MedTrace Logo

Feasibility of a Multifaceted Program to Reduce Cardiovascular Complications of Air Pollution

NCT06261606 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-03-05

No results posted yet for this study

Summary

The main goal of this clinical trial is to evaluate the feasibility of conducting a large-scale clinical trial testing a program containing several aspects for reducing the effects of air pollution on cardiovascular health (which is named the hybrid program hereafter) in adult patients (18 years or older) with atherosclerotic cardiovascular disease. Furthermore, we seek to answer how much patients adhere to and are satisfied with implementing the hybrid program, and what problems executing this program will bring for patients.

Conditions

Interventions

OTHER

Hybrid strategy

A hybrid strategy inclusive of: 1. A one-page flashcard describing the adverse cardiovascular effects of air pollution and individual-level strategies to mitigate these effects 2. Alerting patients on polluted days (defined as air quality index (AQI) ≥ 131 \[33\]) by sending cell phone text messages and recommending to not go outdoors or minimize outdoor activities (especially exercising) on those days. This will also be accompanied by periodic phone calls to ascertain that the patients receive the messages and are attentive to them. 3. Wearing KN-95 facemasks (provided by the investigators of this study) as a physical barrier against air pollution on highly polluted days (defined as AQI ≥ 131) in case the patient cannot avoid going outdoors 4. Dietary intervention by encouraging patients to consume citrus fruits during days with AQI ≥ 131

Sponsors & Collaborators

  • Parham Sadeghipour

    lead OTHER

Principal Investigators

  • Parham Sadeghipour, M.D · Rajaie Cardiovascular Medical and Research Center

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-28
Primary Completion
2024-03-31
Completion
2024-03-31

Countries

  • Iran

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06261606 on ClinicalTrials.gov